Osteoporosis therapeutics market the reason for bone metabolism sector growth

The osteoporosis therapeutics market is the primary reason for the continued growth of the global bone metabolism sector, according to a market report from healthcare specialists, "Bone Metabolism Therapeutics Market to 2018." The revenue of the osteoporosis therapeutics market alone has approximately 68% of the total bone metabolism revenue - far outweighing the other components of the market, Paget's disease of bone, hyperparathyroidism and bone metastases.

The strong performance of the osteoporosis therapeutics market is expected to continue, with forecasters predicting it to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018.

The growth in the osteoporosis therapeutics market can be put down to factors such as, a rising elderly population in all seven top pharmaceutical markets along with increasing osteoporosis diagnosis rates and osteoporosis treatment rates.

The overall global bone metabolism therapeutics market for the four indicators (which includes osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases) has grown from $10.1 billion in 2002, to reach $15 billion in 2010, growing at a CAGR of 5.2%.

However, due to a strong pipeline, the bone metastases market is expected to contribute more notably over the coming years.

In contrast, the global hyperparathyroidism therapeutics is expected to show less impressive growth, declining at a negative CAGR of 1.3% from $1.32 billion in 2010 to $1.17 billion in 2018. This downturn is attributed primarily to the patent expiry of the three approved treatments, Sensipar, Zemplar and Hectorol during this time period.

For more information on the osteoporosis therapeutics market, see the latest research: Osteoporosis Therapeutics Market Report

Follow us on Twitter @CandMResearch